Home › Bladder Cancer › NCT04979156

LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Patients must be 18 years of age or older.
2. Patient presenting for resection of papillary bladder tumor visualized on cystoscopy

   1. New bladder tumor
   2. Recurrent tumors
3. Tumor \<3cm

Exclusion Criteria:

1. Patient unwilling to undergo en bloc resection
2. Non papillary lesions/tumors

About the study

Conventional monopolar or bipolar transurethral resection of bladder tumors is the most common method for resection of a bladder mass. En bloc resection has demonstrated success in the literature utilizing different techniques and lasers, including utilizing the Ho:YAG and Tm:YAG lasers. A recent metanalysis revealed several benefits to laser en bloc resection including less complications and lower recurrence rate.22 Subsequently, laser technology has also advanced with the development of a super pulsed TFL which overcomes many limitations of prior traditional lasers. Olympus' SOLTIVE™ TFL, which has demonstrated improved maneuverability and control, has a shallow depth of tissue penetration at 0.15mm leading to precise resection and optimal hemostasis. Despite these beneficial characteristics and qualities along with the promising utility of en bloc resection, the Olympus SOLTIVE™ TFL has not been described in en bloc resection of bladder tumors. The investigator seek to determine if the proposed benefits of this device can be realized both pathologically and clinically in en bloc resection of bladder tumors.

What is being tested

• SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors (procedure)

Sponsor: University of Kansas Medical Center · Participants: 20 · Started: Nov 4, 2021

Contact the study team

• Jane Ledesma · Phone: 9135888721

Official record on ClinicalTrials.gov — NCT04979156

Locations in the U.S.

Conditions

• Bladder Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.